Publicaciones en las que colabora con JAVIER PUENTE VÁZQUEZ (9)

2017

  1. The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges

    Expert Review of Anticancer Therapy, Vol. 17, Núm. 3, pp. 217-226

2015

  1. A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer

    Clinical and Translational Oncology, Vol. 17, Núm. 4, pp. 330-338

  2. New Challenges in Kidney Cancer Management: Integration of Surgery and Novel Therapies

    Current Treatment Options in Oncology, Vol. 16, Núm. 3

  3. Renal cell cancer metastases to esophagus and stomach successfully treated with radiotherapy and pazopanib

    Anti-Cancer Drugs, Vol. 26, Núm. 1, pp. 112-116

2013

  1. Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice

    Oncology (Switzerland), Vol. 84, Núm. 5, pp. 255-264

2012

  1. Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.

    Cancer metastasis reviews, Vol. 31 Suppl 1

2011

  1. Optimizing first-line treatment in non-small cell lung cancer with bevacizumab

    Cancer and Chemotherapy Reviews, Vol. 6, Núm. 1, pp. 28-36

2007

  1. Autoimmune phenomena as prognostic markers of response to adjuvant interferon therapy for melanoma

    Clinical and Translational Oncology

  2. Tratamiento del melanoma metastásico

    Revisiones en Cancer, Vol. 21, Núm. 4, pp. 187-196